A retrospective evaluation of 215 consecutive recipients of high-dose chemotherapy (HDC) and autologous stem cell rescue (ASCR) was conducted to ascertain the incidence, temporal course, and outcome of varicella zoster virus (VZV) infection. Herpes zoster was identified in 40 individuals at a median of 69 days following ASCR. Six of these cases occurred at a median of 33 days prior to ASCR but following the initiation of high doses of stem cell mobilization chemotherapy. Twenty-five percent of patients demonstrated cutaneous or systemic dissemination and 32.5% required medical intervention for post-herpetic neuralgia. All except two individuals received antiviral chemotherapy. One patient with active VZV infection died of multiorgan failure 39 days after ASCR. Multivariate analysis of risk factors disclosed the significance of prophylactic acyclovir use in Herpes simplex virus seropositive individuals in reducing the risk of VZV infection. Moreover, the use of busulfan, thiotepa and carboplatin as the conditioning chemotherapy regimen was associated with an increased risk of subsequent VZV infection. The incidence of VZV reactivation after HDC and ASCR is similar to that observed following bone marrow transplantation but has an earlier onset. This may be related to an earlier induction of immunosuppression by stem cell mobilization chemotherapy administered prior to ASCR. We demonstrated a marked reduction in the proliferative and synthetic capacities of peripheral blood mononuclear cells obtained prior to and following stem cell mobilizing chemotherapy. Moreover, greater than 80% of VZV infections occurred within 6 months following ASCR and late cases were seldom observed compared to allogeneic and autologous bone marrow transplantation. The role of antiviral chemoprophylaxis during the period of maximum immunocompromise needs to be studied further in the HDC-ASCR setting.
Varicella zoster virus (VZV), a human alpha-herpes virus, is the etiologic agent of varicella in childhood after which it assumes dormancy in the dorsal root ganglia. The virus may reactivate in the elderly or during periods of immunosuppression such as that following allogeneic, syngeneic, or autologous bone marrow transplantation (BMT). In the latter setting, VZV reactivation may be associated with considerable morbidity and occasional mortality. A recent trend has been the increasing use of high-dose chemotherapy and autologous stem cell rescue (HDC-ASCR) for a variety of hematologic malignancies and solid tumors. It has been suggested that the duration and severity of immunosuppression may be less following HDC-ASCR compared to BMT. [1] [2] [3] Since the incidence of VZV reactivation increases with the degree of immunosuppression, 4 it could be postulated that the incidence of VZV reactivation may be lower after HDC-ASCR compared to BMT. Furthermore, HDC-ASCR may be preceded by one or more courses of relatively high-dose stem cell mobilization chemotherapy which may itself be significantly immunosuppressive. This could lead to an earlier manifestation of VZV than that observed following BMT. The aim of this study was to ascertain the incidence, temporal course, and outcome of VZV reactivation following HDC-ASCR.
Materials and methods

Patients
Two hundred and fifteen consecutive patients underwent HDC-ASCR between March 1993, and January 1997, at the University of Connecticut Health Center (Farmington, CT, USA) and were eligible for retrospective evaluation. Clinical data were obtained from comprehensive chart reviews (Table 1) . Localized herpes zoster was defined as fewer than six vesicles beyond the confines of the primary dermatome. Disseminated herpes zoster consisted of six or more vesicles beyond the confines of the primary dermatome and/or visceral involvement. Finally, varicella was defined as a generalized vesicular eruption without prior dermatomal localization.
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Underlying malignancies included carcinoma of the breast (n = 105), non-Hodgkin's lymphoma (n = 72), multiple myeloma (n = 14), acute leukemia (n = 7), ovarian carcinoma (n = 8), and other solid tumors (n = 9). Stem cell mobilization chemotherapeutic regimens consisted of etoposide 60 mg/kg body weight intravenously (40 patients, 42 courses), etoposide 60 mg/kg body weight intravenous and cyclophosphamide 3 g/m 2 intravenously (19 patients, 21 courses), and etoposide 60 mg/kg body weight intravenously, cyclophosphamide 3 g/m 2 intravenously and paclitaxel 200 mg/m 2 intravenously (TEC) (152 patients, 377 courses). Four patients underwent stem cell collection following the administration of growth factor only. The HDC regimen consisted of busulfan 16 mg/kg body weight orally, carboplatin 800-1000 mg/m 2 intravenously and thiotepa 500-700 mg/m 2 intravenously (BUCAT) (n = 137), busulfan 16 mg/kg body weight orally, cyclophosphamide 90 mg/kg body weight intravenously and etoposide 60 mg/kg body weight intravenously (BUCET) (n = 73), and other regimens (n = 5). Methylprednisolone, initially 0.5 mg/kg intravenously or orally and subsequently on a tapering schedule, was initiated from day +2 for a median of 6 weeks to combat the effect of cutaneous autoaggression syndrome.
All individuals who were sero-positive for the Herpes simplex virus (HSV) received prophylaxis with acyclovir 250 mg/m 2 intravenously every 8 h from the initiation of HDC until recovery of blood counts following ASCR, and then 400 mg orally twice daily until day +50 following ASCR. The VZV serologic status of 210 patients was studied prior to the initiation of stem cell mobilization chemotherapy. A diagnosis of VZV reactivation was established clinically and confirmed subsequently in all patients by culture and direct fluorescent antibody staining (Merifluor R VZV, Meridian Diagnostics, Cincinnati, OH, USA) of fluid and scrapings obtained from vesicles. Routine cytomegalovirus (CMV) surveillance cultures were not performed. Blood, urine or other specimens were submitted for culture (Chemicon, Temecula, CA, USA) and polymerase chain reaction analysis when patients exhibited suspicious clinical features such as fever, cough or rhinorrhea, gastro-intestinal symptoms, hemorrhagic cystitis, elevated hepatic transaminases, thrombocytopenia, reversal of the neutrophil: lymphocyte ratio, fluid retention or constitutional symptoms. Similarly, suspicious lesions were scraped and submitted for HSV culture.
Several variables were examined as potential risk factors for VZV reactivation. These included age, sex, underlying malignancy, type of conditioning chemotherapy regimen, duration of corticosteroid use, and administration of prophylactic acyclovir in HSV-seropositive patients. Contingency table (x   2   ) analyses were used to estimate the statistical significance of each discrete variable. Time to infection was analysed using a Cox proportional hazards regression model. Models were fitted using age, sex, underlying malignancy, type of conditioning chemotherapy regimens, prophylactic administration of acyclovir, and corticosteroid therapy as candidate predictors of VZV infection.
Proliferation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood of six healthy donors and five patients by Ficoll-Hypaque gradient centrifugation (Sigma, St Louis, MO, USA). A total of 2 × 10 6 cells suspended in 200 l of culture medium per well were cultured in triplicate in 96-well U-bottomed plates (Costar, Cambridge, MA, USA) with phytohemagglutinin (PHA) (Sigma) 2 g/ml or with anti-CD3 antibody (Coulter, Miami, FL, USA) 50 l/10 6 cells for 5 days in the presence or absence of interleukin-2 (IL-2) 50 units/ml. Radioactive thymidine 3 HTdR (Nen, Boston, MA, USA) 1 Ci/well was added for the final 16 h of culture. Cells were harvested in a Titertek semi-automatic cell harvester (Skattron, Sterling, VA, USA) and thymidine incorporation was estimated by a Beckman liquid scintillation counter (Beckman Instruments, Irvine, CA, USA). 6 
Interleukin-2 secretion by PBMC
Peripheral blood mononuclear cells obtained from six normal donor and five patients were treated with PHA and anti-CD3 antibody as described above and supernatants of these cultures were removed after 72 h of stimulation. The presence of IL-2 in this supernatant was quantitated with IL-2 ELISA kits (Endogen, Woburn, MA, USA) in accordance with the manufacturer's directions.
Results
Incidence of VZV infection
Over 95% of the 210 patients tested were sero-positive for VZV prior to the initiation of stem cell mobilization chemotherapy. The median number of days from the beginning of stem cell mobilization chemotherapy to ASCR was 85 (range 0-240 days). The median follow-up from the initiation of stem-cell mobilization chemotherapy and from ASCR has been 23 months and 20 months (range 1-58 months), respectively. A total of 40 individuals (18.6%) developed VZV reactivation at a median of 69 days (range −108 days to +488 days) following ASCR ( Figure 1) . Six of these patients presented with a VZV eruption prior to ASCR but following the commencement of stem cell mobilizing chemotherapy at a median of 33 days (range −9 to −108) prior to ASCR. The remaining 34 patients (15.8%) developed VZV reactivation after ASCR at a median of 80 days following transplantation (range 6 to 488 days). A single seronegative patient developed disseminated herpes zoster. All other patients who manifested with VZV reactivation were seropositive previously. Nineteen of the 40 individuals to develop VZV infection were also seropositive for the Herpes simplex virus and received prophylaxis with acyclovir. Only one of these patients developed VZV reactivation while receiving acyclovir. However 17 of the remaining 133 HSV sero-positive individuals developed VZV infection following the completion of prophylactic acyclovir therapy.
Clinical features and outcome of VZV infection
All 40 patients presented with a cutaneous vesicular eruption ( Table 2 ). The most frequently involved sites included thoracic and cranial nerve dermatomes followed by lumbosacral and cervical dermatomes. Ten patients (25%) also developed cutaneous dissemination. Varicella zoster virus was identified in the urine (n = 2) and blood (n = 1) of two individuals. One of these patients died 39 days after ASCR from multi-organ failure with active VZV infection. All patients were left with some cutaneous scarring but there was no instance of bacterial superinfection. The most significant adverse effect was post-herpetic neuralgia and consisted of nerve root pain which persisted for more than 4 weeks after the vesicular eruption and required medical intervention. Thirteen patients (32.5%) developed postherpetic neuralgia.
Risk factors of VZV infection
All 215 patients were included in the statistical analysis (Table 3 ). There was no significant difference in the incidence of VZV reactivation among the 59 patients who died within 1 year of ASCR (incidence 22%) and the 156 individuals who were followed beyond a year following ASCR (incidence 17.3%). In fact, 85% of cases occurred within 6 months after ASCR. The only variable to achieve statistical significance in univariate analysis was prophylactic use of acyclovir (P = 0.02). The most informative Cox proportional hazards regression model included chemotherapy regimen (BUCAT) and use of prophylactic acyclovir terms. The use of BUCAT chemotherapy indicated a 2.7 times greater probability of VZV infection whereas the use of prophylactic acyclovir reduced the chance of VZV infection by 58%.
Treatment of VZV infection
All except two patients received antiviral chemotherapy. Once the diagnosis had been established, treatment consisted of intravenous acyclovir 10 mg/kg body weight every 8 h or 800 mg orally five times/day to complete 7 to 10 days of therapy. Most individuals also received intravenous immunoglobulins to a total dose of 1-2 g/kg body weight. All patients responded to treatment.
Other viruses
A total of 88 patients (40.9%) were seropositive for CMV prior to the initiation of TEC chemotherapy. There were 35 (16.3%) documented cases of CMV infection occurring at a median of 43 days (range day −104 to day +87) following stem cell infusion. Individuals who developed CMV infection received ganciclovir 5 mg/kg intravenously twice daily for 7 days and once daily for another 7-14 days. One hundred and thirty-four patients (62.3%) were seropositive for HSV. Eighteen patients (8.4%) developed HSV infection at a median of 44 days (range day −127 to day +83) prior to stem cell infusion. Figure 2 demonstrates the proliferative responses of PBMC in patients prior to the initiation of TEC, following the completion of final cycle of TEC, and in normal donors. Pro- (Table 4) .
Proliferative and secretory responses of PBMC
Discussion
Varicella zoster virus is a common opportunistic pathogen after BMT and usually represents reactivation of the latent virus. This reactivation results from the profound immunosuppression observed after all varieties of BMT. The incidence of VZV reactivation by 1 year following allogeneic, syngeneic and autologous BMT varies from 16.6% to 67%. 5, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Moreover, nearly 26% of individuals can develop subclinical VZV reactivation detected by a regained lymphocyte proliferative response to the VZV antigen. 10 Such individuals may not necessarily manifest clinically. 10 The median onset of VZV reactivation occurs at 5 to 6 months following BMT. 5, 9, 12, 15 However, the onset may be sooner in children. 7, 11 In children, 67% to 87% of cases occur within 6 months after BMT 7,11 whereas in adults, over 50% of cases develop more than 6 months following BMT. 8, 16 An incidence of VZV reactivation of 18.6% observed in our series of patients receiving HDC-ASCR does not appear to be significantly different from the incidence seen after BMT. However, the median onset of VZV reactivation of just over 2 months following ASCR is much earlier than that following BMT and could be explained by the induction of immunosuppression prior to ASCR following several cycles of stem-cell mobilization chemotherapy. Furthermore, the majority of cases occurred within 6 months of ASCR unlike the observations in adult BMT patients. It has been noted that the duration and degree of immune compromise is greatest following allogeneic BMT, intermediate with syngeneic BMT, and least after autologous BMT. 18, 19 However, even in the latter situation, cellular immunity may remain impaired for over 2 years. 20 Similar results have been demonstrated after HDC and HDC-ASCR. 1 In children, there has been no significant difference in immunologic recovery following autologous BMT and ACR. 7 However, other investigators have demonstrated that CD8 positive cells, natural killer cells and lymphokine-activated killer activity are reconstituted far more rapidly after HDC-ASCR. [21] [22] [23] [24] Furthermore, immunity against CMV is reconstituted within the first 3 months following autologous stem cell infusion in CMV-seropositive individuals. 25 Our studies suggest that use of dose-intense stem cell mobilizing chemotherapy regimens are quite capable of inducing marked abnormalities in the proliferative and synthetic capacities of PBMC. When these results are evaluated in the light of faster immune reconstitution following HDC-ASCR, such patients may be at risk for infection not only with VZV but also other viruses such as CMV and HSV even prior to stem cell infusion. However, because of the relative rapidity of immunologic reconstitution, late viral infections beyond 4 to 6 months following HDC-ASCR would be a rarity. These clinical findings were quite evident in our study.
The incidence of cutaneous and visceral dissemination varies from 20 to 45%. 5, 12, 16 Nearly one-quarter to one-third of cases of VZV reactivation are complicated by scarring, alopecia, neurologic dysfunction, or post-herpetic neuralgia. 5, 12, 16 The most common complication, post-herpetic neuralgia, occurs in up to 30% of patients. 5, 16 Mortality is negligible after autologous BMT but may approach 10% in the allogeneic setting. 5 Less common complications include encephalitis and pneumonitis, the latter being associated with an extremely high mortality rate. 5 Most investigators recommend 7 to 10 days of treatment with antiviral chemotherapy. Newer oral agents such as famciclovir and valacyclovir are being utilized increasingly because of their ease of administration and improved absorption from the gut. 4 The routine use of IVIG cannot be recommended because immunoglobulin levels do not decrease significantly after HDC-ASCR 2,3 and preparations of IVIG are costly. In one large series, there was no significant difference in the incidence of VZV infection following allogeneic, syngeneic, or autologous BMT. 16 However, others have demonstrated an increased incidence in allogeneic recipients compared to patients receiving syngeneic BMT for acute leukemia. 5, 9 Similarly, although most investigators have failed to establish a significant impact of acute and chronic graft-versus-host disease on subsequent VZV reactivation, 8, 10 one large series did demonstrate the significance of these variables. 5 Varicella zoster virus infections have been observed most frequently in patients with Hodgkin's disease and non-Hodgkin's lymphoma, followed by acute leukemia. 12, 16 A diagnosis of solid tumor and chronic myelogenous leukemia is associated with a decreased risk. 5, 12 Herpes zoster virus seropositivity and a prior history of VZV reactivation following an initial diagnosis of Hodgkin's disease are also established risk factors. 13, 16 Similarly, age greater than 10 years and use of total body irradiation also identify patients at risk for subsequent VZV reactivation. 16 However, cytomegalovirus serology, neutrophil recovery, and prophylactic use of acyclovir until 100 days following BMT have failed to make an impact on the incidence of VZV infection.
14 In fact, some investigators have utilized acyclovir in relatively high doses for up to 6 months after transplantation. 17, 26 In one study, although none of these patients developed VZV reactivation while receiving prophylactic acyclovir, the cumulative probability of developing VZV infection exceeded 30%. 27 Univariate analysis of risk factors indicated that the use of acyclovir prophylaxis in HSV-seropositive patients was also protective for VZV infection. Multivariate analysis confirmed this finding and also determined the significance of BUCAT conditioning chemotherapy in increasing the risk for subsequent VZV infection. The number of patients less than 10 years of age or with an underlying diagnosis of Hodgkin's disease was far too low to achieve significance in our analysis.
This study represents the largest report of VZV infection following HDC-ASCR. The incidence of viral reactivation appears to be similar to that reported in BMT recipients. However, VZV infection seems to occur 2-4 months earlier after HDC-ASCR compared to allogeneic and autologous BMT. Some of the infections can occur even prior to stem cell infusion in patients given stem cell mobilization chemotherapy because such an approach renders these patients immunocompromised even prior to HDC-ASCR. Furthermore, unlike BMT where late infection with VZV are evident quite frequently, most cases of VZV occur within the first 6 months following HDC-ASCR and late infections are seldom observed. This phenomenon may be related to the more rapid reconstitution of the immune system following HDC-ASCR. Treatment with antiviral chemotherapy is recommended in these immunocompromised individuals. However, the role of chemoprophylaxis during the period at risk is controversial and warrants further study. Moreover, the role of immunization with varicella vaccine, which is being studied currently, may be associated with reduced morbidity and should be investigated further. 27, 28 
